Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Pressures Lower Profits For Chinese Drug Chain Nepstar, While Healthcare Reform Has Opposite Effect On Hospital Chain Chindex - China Earnings Roundup (Part 1)

This article was originally published in PharmAsia News

Executive Summary

Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.

You may also be interested in...



Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets

As China opens up its private hospital market and a new wave of investment, major players such as Chindex International Inc. are reevaluating and repositioning themselves to benefit from the growing private infrastructure.

China Nepstar Chain Drug Store Eyes Quality As Quantities Grow Rapidly

Nepstar says it needs to focus on retaining customer loyalty at fewer, but more productive stores, to keep strong margins even as drugs sales by volume soar in China.

China’s Private Hospital Market Takes Flight

Non-public hospitals are blossoming in China, growing at 19% in 2011, and the trend is accelerating, reflected by 20.5% growth in the first five months of 2012.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel